Skip to main content

Table 1 Clinicopathological parameters, methylation and genetic alterations and its relation to cluster status

From: DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma

  All Samples (n = 115) Cluster A (n = 81) Cluster B (n = 34) p-value
Age (median ± SD) 65.0 ± 11.6 67.0 ± 11.5 63.0 ± 11.2 0.1031
Gender
 Male 66 42 24 0.0642
 Female 49 39 10
Tumor diameter (mm, median ± SD) 70.0 ± 41.6 55.0 ± 36.1 95.0 ± 38.5 < 0.0011
Morphological grade
 G1 16 16 0 < 0.0012
 G2 46 40 6
 G3 34 20 14
 G4 18 5 13
T Stage
 T1 50 47 3 < 0.0012
 T2 25 17 8
 T3 39 17 22
 T4 1 0 1
M stage
 M0 87 70 17 < 0.0012
 M1 28 11 17
TNM
 I 49 46 3 < 0.0012
 II 14 12 2
 III 24 12 12
 IV 28 11 17
Progress (n = 87)
 No 64 57 7 0.0012
 Yes 23 13 10
Follow Up Status
 Living 39 35 4 < 0.0012
 Living with disease 5 3 2
 Dead in ccRCC 45 20 25
 Dead 26 23 3
Average methylation (median ± SD) 0.3215 ± 0.0136 0.3196 ± 0.0105 0.3344 ± 0.0127 < 0.0011
Loss Chr 9p
 WT 73 62 11 < 0.0012
 Loss 42 19 23
Loss Chr 9q
 WT 75 62 13 < 0.0012
 Loss 40 19 21
Loss Chr 14q
 WT 76 60 16 0.0052
 Loss 39 21 18
Risk score (n = 114) [33]
 Low Risk 63 45 18 0.7452
 High Risk 51 35 16
  1. Differences between groups are compared using 1 Mann-Whitney Test and 2 χ2-test
\